Indianapolis, Indiana-headquartered Eli Lilly launched Copellor (Ixekizumab) in India to treat adults that have moderate-to-severe plaque psoriasis and who are candidates for systemic therapy or phototherapy. The drug will also be available for the treatment of adult patients with active psoriatic arthritis. Psoriasis is a chronic auto-immune disorder of the...
Biocon receives authorization to sell Psoriasis drug in India
Biocon (a Biotechnology Company with headquarters in Bangalore, India) has received the marketing authorization from the Drugs Controller general of India for Novel Biologic Itolizumab (used for the treatment of chronic plaque Psoriasis). Itolizumab has an excellent safety profile as indicated during the 52-week clinical study conducted in India. This...